Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04392206 · ClinicalTrials.gov registry record · Phase 1
AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses
A Phase 1 study of End Stage Renal Disease, sponsored by Houssam Farres, M.D..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT04392206: Recruiting Phase 1 study of End Stage Renal Disease, sponsored by Houssam Farres, M.D..
NCT04392206 is a Phase 1 study of End Stage Renal Disease that is actively recruiting participants, run by Houssam Farres, M.D.. The registered enrollment target is 15 participants, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04392206, a Phase 1 study of End Stage Renal Disease, is actively recruiting participants, sponsored by Houssam Farres, M.D..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
Researchers are evaluating the safety of allogeneic Adipose Derived Mesenchymal Stem Cells (AMSC) use during hemodialysis arteriovenous fistula and arterial bypass creation and its efficacy on improving access maturation and primary anastomotic patency.
Primary Outcome
Evaluate the safety of AMSC administration by assessing the number of participants to experience an adverse event as defined by inflammation, infection (local or systemic), aneurysm formation, clinically significant increase or decrease in blood flow or thrombosis formation as evaluated through physical exam and ultrasound.
Conditions Studied
Interventions
- DRUG Adipose Derived Mesenchymal Stem Cells
Study Locations (1)
Florida
- Mayo Clinic in Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2020-05-15 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
What NCT04392206 shows while recruiting
NCT04392206 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (98% lower).
The record links to 1 condition, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which Adipose Derived Mesenchymal Stem Cells is the first listed.
NCT04392206 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT04392206 about?
NCT04392206 is a clinical study titled "AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses". Researchers are evaluating the safety of allogeneic Adipose Derived Mesenchymal Stem Cells (AMSC) use during hemodialysis arteriovenous fistula and arterial bypass creation and its efficacy on improving access maturation and primary anastomotic patency.
What is the current status of trial NCT04392206?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2020-05-15. Estimated completion is 2027-06.
What conditions does trial NCT04392206 study?
This clinical trial studies the following conditions: End Stage Renal Disease.
What interventions are being tested in trial NCT04392206?
The interventions under investigation include: Adipose Derived Mesenchymal Stem Cells (DRUG).
Who is sponsoring clinical trial NCT04392206?
This trial is sponsored by Houssam Farres, M.D., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04392206 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04392206's enrollment target sits among peer trials
15 74th of 86 higher than 13 of 86 other End Stage Renal Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other End Stage Renal Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
RECRUITING · Phase 1
-
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
ACTIVE NOT RECRUITING · Phase 1
-
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
COMPLETED · Phase 1
-
Plazomicin Study in ESRD Patients Receiving IHD
COMPLETED · Phase 1
-
A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin
COMPLETED · Phase 1
-
Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI